Randomized trials evaluate antidepressant efficacy in drug treatment-naive patients, suggesting alternative approaches for guidelines.
Randomised clinical trials with the same study design for granting a marketing authorisation are used to draw up depression guidelines. These randomised clinical trials have several limitations. These include that depression of the participants in these randomised clinical trials is heterogeneous to varying degrees and the natural resilience mechanism is insufficiently controlled. It is preferable to base antidepressant treatment guidelines on the results of pragmatic trials by a fixed group of primary and secondary care reporters in drug treatment-naive patients.
No takes yet. Share an insight, caveat, or question.
A.J.M. Loonen (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: